Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 54, Issue 1, Pages 262-276Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm1011319
Keywords
-
Categories
Ask authors/readers for more resources
The myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are a heterogeneous but related group of hematological malignancies characterized by clonal expansion of one or more myeloid lineages The discovery of the Jak2 V617F gain of function mutation highlighted Jak2 as a potential therapeutic target in the MPNs Herein, we disclose the discovery of a series of pyrazol-3-yl pyrimidin-4-amines and the identification of 9e (AZD1480) as a potent Jak2 inhibitor 9e inhibits signaling and proliferation of Jak2 V617F cell lines in vitro demonstrates in vivo efficacy in a TEL-Jak2 model, has excellent physical properties and preclinical pharmacokinetics, and is currently being evaluated in Phase I clinical trials
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available